Cohance Lifesciences appoints Abhimanyu Ojha as CFO from October 12, 2026

Management Changes View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹442.80

prior close

₹446.60

announcement price

After-mkt

timing

Nifty Smallcap 250market+1.1%-0.5% vs market

Pharmaceuticals peers, median of 167sector-0.1%+0.8% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Smallcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-1.1

15m

-0.8

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+1.1-0.5-0.1+0.8

Next day

-1.5+1.5-3.0-0.1-1.4

+1.1+1.5-0.4-0.3+1.4

+4.0+0.3+3.7-1.0+5.0

+4.9+0.4+4.6-0.8+5.8

+3.1-0.8+3.9-2.3+5.3

+2.1-4.1+6.2-4.7+6.7

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences has appointed Mr. Abhimanyu Ojha as Chief Financial Officer and Key Managerial Personnel effective October 12, 2026, based on the recommendation of its Nomination and Remuneration Committee. Ojha brings over 20 years of finance leadership, most recently as Global CFO and President Finance at Intas Pharmaceuticals, with prior senior roles at Viatris, Sun Pharma, and Ranbaxy. His expertise spans financial strategy, M&A, treasury, tax, and risk management.

Likely market impact

Strong external hire with deep pharma finance experience. Positive signal on financial discipline and governance.